News | Sutro Biopharma, Inc.

American Association for Cancer Research (AACR) 2018 – STRO-002 Poster

American Association for Cancer Research (AACR) 2018 – STRO-002 Poster Discovery and Activity of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian and Endometrial Cancer STRO-002 AACR 2018 Poster...

Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research

Press Releases

Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research – Phase 1 Trial Planned for Late 2018 – Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s...

American Association for Cancer Research (AACR) 2018 – STRO-002 Abstract

Presentations

American Association for Cancer Research (AACR) 2018 – STRO-002 Abstract Generation and Activity of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer Folate receptor alpha (FolRa) is a glycosylphosphatidylinositol linked cell-surface...

Society for Gynecologic Oncology (SGO) 2018 – STRO-002 Abstract

Presentations

Society for Gynecologic Oncology (SGO) 2018 – STRO-002 Abstract Preclinical Activity and Safety of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer Objectives: Folate receptor alpha (FolRa) is a cell-surface glycoprotein, highly expressed...

Society for Gynecologic Oncology (SGO) 2018 – STRO-002 Poster

Presentations

Society for Gynecologic Oncology (SGO) 2018 – STRO-002...

STRO-001 – Publication Highlights

Presentations

STRO-001 – Publication Highlights Pan Pacific Lymphoma, 2018 HIGH FREQUENCY OF CD74 EXPRESSION IN B-CELL NON-HODGKIN’S LYMPHOMA (NHL) AND TARGETING WITH STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) WITH POTENT IN VITROCYTOTOXICTY AND IN...